Day One Biopharmaceuticals, Inc. successfully completed its acquisition of Mersana Therapeutics, Inc. on January 6, 2026, with 3,029,135 shares (approximately 60.57%) tendered at an offer price totaling around $128.8 million. The merger included contingent value rights linked to specific future milestones for the drug Emi-Le.